about
Role of mucins in the skin during benign and malignant conditions.Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL instrument.Time trends, ethnicity and risk factors for eczema in New Zealand children: ISAAC Phase Three.An optimised method for the proteomic profiling of full thickness human skin.Maximizing patient adherence for optimal outcomes in psoriasis.The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies.Biological therapies in moderate and severe psoriasis: perspectives and certainties.A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.Antibacterial photosensitization through activation of coproporphyrinogen oxidase.Epidemiology of Frequently Occurring Skin Diseases in Italian Children from 2006 to 2012: A Retrospective, Population-Based Study.Impact of the number of dermatologists on dermatology biomedical research: a Canadian study.Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study.Age and Spatial Peculiarities of Non-neoplastic Diseases of the Skin and Subcutaneous Tissue in Kazakhstan, 2003-2015.Psychosocial morbidity in skin disease.How well is the outcome of patch testing remembered by the patients? A 10-year follow-up of testing with the Swedish baseline series at the Department of Dermatology in Örebro, Sweden.Effects of time and recall of patch test results on quality of life (QoL) after testing. Cross-sectional study analyzing QoL in hand eczema patients 1, 5 and 10 years after patch testing.Development, Characterization, and Evaluation of Novel Broad-Spectrum Antimicrobial Topical Formulations from (Roxb.) W. Watson Essential Oil
P2860
Q35596376-D8D4B0E6-74AD-4059-8B91-98C7F16177E3Q35629124-BA997B88-E1C3-4F05-A381-BBB5BB664AB5Q37077500-F2DA022D-2E21-4679-921E-D54B3C8BD125Q37113149-6A0D267B-4112-47D0-A380-87DC8144AA24Q37867174-7DF43520-6A8F-4C49-BB99-CF3330C83125Q38038057-72967D81-D62B-4E9B-AE1D-E7F0F3C7549DQ38419792-F51E55FC-19B6-4285-9FE7-C00AAF16042EQ38858335-E597BE7D-CD18-4CD7-9B21-F5D7C27539CFQ40121653-26EA8A62-C560-4527-B39A-274BA23885FDQ41065570-9F5F2B4F-0543-4F32-8D95-85E0CA286693Q43624568-4036E48B-1DFC-4519-8E17-D96C748853C6Q44423627-8D33A9BD-E745-4FFD-A0C6-6539104EF5A8Q47098623-05D5EE20-9522-4B1B-82B2-666E095BC0FFQ47823378-7F4BA74C-5E3D-4601-80D5-456DE5830F9BQ50765803-BE59AFF4-0A6A-4541-8B8F-2EF3C26D900AQ50983658-FCC9E43F-1551-44A9-924C-620C9B460B6CQ57095424-E53D7718-148C-44FE-BFE7-EAB5D81410D6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Burden of skin diseases.
@en
Burden of skin diseases.
@nl
type
label
Burden of skin diseases.
@en
Burden of skin diseases.
@nl
prefLabel
Burden of skin diseases.
@en
Burden of skin diseases.
@nl
P2860
P356
P1476
Burden of skin diseases.
@en
P2093
Mohammad K A Basra
Muhammad Shahrukh
P2860
P304
P356
10.1586/ERP.09.23
P577
2009-06-01T00:00:00Z